Subcutaneous Efgartigimod Expands Payer Potential For Argenx’s Drug

Offers gMG Patients Freedom From I.V. Treatment

With positive Phase III data for the injectable version of its myasthenia gravis therapy, the company expects most patients to use it over intravenous Vyvgart, opening more avenues for reimbursement.

Infusion of a hospital — argenx announced topline results for its subcutaneous formulation of efgartigimod • Source: Shutterstock

Only four months after approval of its intravenous drug Vyvgart (efgartigimod) for generalized myasthenia gravis (gMG), argenx N.V. is forecasting that the vast majority of patients who are candidates for treatment eventually may switch to the subcutaneous formulation after a successful Phase III clinical trial.

The company announced topline data on 22 March from the 110-patient ADAPT-SC study of subcutaneous efgartigimod in gMG, showing that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

31 Jul 2025

• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

31 Jul 2025

• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.